What a prescriber considers

When a New Zealand medical practitioner considers prescribing medicinal cannabis, they are not making a single decision. They are weighing evidence, safety, legality, and the patient’s own goals in a structured conversation. Under the Misuse of Drugs Act and the Medicinal Cannabis Scheme run by the Ministry of Health, prescribing is a regulated clinical act, not a general licence to use cannabis, and not a “natural cure” shortcut.

This page explains the factors a prescriber weighs before writing a prescription, and gives you a practical checklist to understand the conversation. It does not tell you whether you should take cannabis, or which product is right for you. That decision belongs to your doctor or specialist.

---

The regulatory frame the prescriber works inside

A prescriber in New Zealand is not free to hand out cannabis like a supplement. The Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (part of Medsafe), operates under the Misuse of Drugs Act 1975. Since 1 April 2020, the scheme has allowed medical practitioners to prescribe cannabis-based products that meet GMP (Good Manufacturing Practice) standards and are approved by the Ministry of Health (Medsafe, 2020).

The key legal point: a prescription is required for every legal medicinal cannabis product. There is no “over-the-counter” cannabis, and there is no legal pathway for a patient to self-select a raw plant and have it dispensed as if it were a herbal remedy. Even the raw flower, when prescribed, is a manufactured pharmaceutical product dispensed through a pharmacy, not a dispensary. The Misuse of Drugs Act 1975 (as amended by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018) sets the framework, and the Medicinal Cannabis Agency (MCA), part of Medsafe, oversees the scheme. Since the scheme’s full commencement on 1 April 2020, products must meet GMP standards and be approved by the Ministry of Health. This is the legal baseline every prescriber works within.

What a prescriber actually weighs up

A prescriber does not start with the product. They start with the person, the condition, and the evidence. The decision to prescribe medicinal cannabis under the Medicinal Cannabis Scheme is a clinical judgement, not a checkbox. Under the Misuse of Drugs Act and the Medicinal Cannabis Scheme, a medical practitioner can prescribe a controlled drug, but they must do so within the same duties of care as any other medicine: assess, inform, monitor, and document.

The core question a prescriber asks is not “does cannabis work?” but “is this the right treatment for this person, at this time, given what else has been tried and what could go wrong?”

The sections below walk through the factors a prescriber weighs, the evidence they consult, and the questions they will ask you. The goal is to help you prepare for that conversation, not to replace it.

The legal frame in New Zealand

Medicinal cannabis products in New Zealand are regulated pharmaceuticals under the Misuse of Drugs Act 1975 and the Medicinal Cannabis Scheme, administered by the Ministry of Health and Medsafe. Since the scheme took effect in 2020, a medical practitioner can prescribe a manufactured cannabis product that meets GMP standards and has been notified to the Ministry of Health. The raw plant material that a patient might obtain elsewhere is not part of this scheme, and smoking raw flower is not a legal route to medicinal cannabis under New Zealand law. The legal products are manufactured pharmaceuticals, oils, capsules, or dried flower for vaporisation, dispensed through a pharmacy against a prescription. (Source: New Zealand Ministry of Health, Medicinal Cannabis Scheme, 2020; Medsafe, 2020.)

Prescribers are not free to prescribe any cannabis product. They must choose from products notified to the Medicinal Cannabis Agency, which are listed on the New Zealand Formulary and meet GMP standards. Products that have not been notified cannot be prescribed legally under the scheme. This is a key gatekeeper: the legal pathway is a regulated pharmaceutical one, not a general licence to use cannabis.

---

The prescribing decision in practice

When a prescriber considers medicinal cannabis, they are not deciding “should this patient use cannabis?” They are answering a narrower question: does this person have a condition where the evidence supports a trial of a specific cannabinoid product, and can they be monitored safely?

In New Zealand, the legal framework is set by the Misuse of Drugs Act and the Medicinal Cannabis Scheme, administered by the Ministry of Health and Medsafe. Under the scheme, a medical practitioner can prescribe a CBD or THC product that meets GMP standards and has been notified to the Ministry of Health. The prescriber must weigh the same factors as for any pharmaceutical: the strength of the evidence, the patient’s other medicines, the risk of adverse effects, and whether the goal is realistic. The scheme does not create a general right to use cannabis; it creates a regulated clinical pathway.

The legal and regulatory context

The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and became fully operational in April 2020. It legalises access to medicinal cannabis products through a prescription from a registered medical practitioner, but it does not legalise recreational use or self-medication. Products must be manufactured to Good Manufacturing Practice (GMP) standards and approved by the Ministry of Health. The scheme also sets quality standards, including limits for contaminants and stability testing.

Medsafe, the New Zealand regulator, oversees product approvals. The Medicinal Cannabis Agency (MCA), part of Medsafe, issues licences to importers, manufacturers and suppliers. The NZ Formulary includes cannabis product monographs, and the New Zealand Ministry of Health publishes the scheme’s regulations. Under the Misuse of Drugs Act 1975, the prescribing of cannabis-based products is legal when the product meets the requirements of the Medicinal Cannabis Scheme, which came into force on 1 November 2020 (New Zealand Ministry of Health, 2020). The scheme legalises access via a prescription from a medical practitioner, and products must meet Good Manufacturing Practice (GMP) standards and be approved by the Ministry of Health. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated products; the legal product is a manufactured pharmaceutical, and the raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary.

PRESCRIBER_DECISION_FRAMEWORK: 1. Confirm the indication is one with at least some peer-reviewed clinical evidence (chronic pain, cancer-related symptoms, refractory epilepsy, palliative care, spasticity in MS). 2. Confirm the patient has exhausted or not tolerated conventional treatments; this is the “last resort” framing most prescribers use. 3. Screen for contraindications: pregnancy/breastfeeding, personal or family history of psychosis or schizophrenia, unstable cardiac disease, severe liver impairment, current substance use disorder. 4. Check for drug interactions: CYP3A4, CYP2C19, CYP2C9 inhibitors/inducers; warfarin, clobazam, olanzapine, ketoconazole, rifampicin, alcohol, sedatives. 5. Choose product form based on onset and duration: inhaled for breakthrough, oral oils for maintenance; match THC:CBD ratio to the dominant symptom. 6. Start low and go slow: prescribe a low dose, titrate by 25% every 3-7 days, monitor for adverse effects. 7. Document the treatment plan: indication, product, dose, titration schedule, review date, and a “stop rule” if no benefit after a defined trial. 8. Monitor at follow-up: pain scores, sleep quality, mood, adverse effects, and interactions with existing medicines. 9. Consider contraindications: unstable cardiovascular disease, current substance use disorder, pregnancy or breastfeeding, and a history of cannabis-induced psychosis. 10. Consider drug interactions: CYP3A4 and CYP2C19 inhibitors/inducers (e.g., clobazam, warfarin, olanzapine) can raise or lower levels of THC and CBD.